Proceedings of the second
Global Vaccine Research Forum

Montreux, Switzerland, 10-12 June 2001

Initiative for Vaccine Research
Vaccines and Biologicals

World Health Organization
Proceedings of the second
Global Vaccine Research Forum

Montreux, Switzerland, 10-12 June 2001

Initiative for Vaccine Research
Vaccines and Biologicals
World Health Organization
Contents

Abbreviations ........................................................................................................................................ v
Executive summary ............................................................................................................................ vii
Progress towards vaccines for HIV/AIDS, malaria and tuberculosis: overview and highlights ................................................................................................................................................................. 1

HIV/AIDS: The biological basis of an AIDS vaccine ................................................................. 1
Malaria: Vaccines against blood stages of malaria parasites ................................................. 2
Malaria: Pre-erythrocytic malaria vaccines ........................................................................... 2
Tuberculosis: Tuberculosis vaccines ......................................................................................... 4
Tuberculosis: Report on the Global Forum on Tuberculosis Vaccines Research and Development ................................................................. 4

The three disease-specific vaccine research and development projects selected by the Task Force ........................................................................................................................................................................ 6

Pneumococcal vaccines .............................................................................................................. 6
Rotavirus vaccines ...................................................................................................................... 7
Meningococcal vaccines ............................................................................................................. 7

New immunization technologies ................................................................................................. 9

A process for identifying and selecting new technologies ......................................................... 9
Priority area: assuring safe and effective vaccine administration .................................... 10
Priority area: systems efficiency .............................................................................................. 11
Priority area: programme effectiveness .................................................................................. 12

New developments in selected areas ......................................................................................... 13

Shigella vaccines .......................................................................................................................... 13
ETEC ........................................................................................................................................... 13
RSV ............................................................................................................................................... 13

New adjuvants ................................................................................................................................. 14

CpGs ............................................................................................................................................... 14
MF59 ............................................................................................................................................... 14
Virosomes ....................................................................................................................................... 14

Clinical trials ...................................................................................................................................... 15

Scientific considerations on quality, safety and regulatory issues for vaccines under development: HIV as a model ................................................................. 15
Issues in clinical trials .................................................................................................................. 16
Views of industry and economic incentives for vaccine development .......... 19
  Manufacturers in developed countries ......................................................... 19
  Manufacturers in developing countries ....................................................... 19
  The European Union: a new supporter of GAVI’s activities ....................... 20

Annex 1: List of participants ........................................................................... 21
Abbreviations

AIDS        acquired immunodeficiency syndrome
ATT         Access to Technologies
BCG         Bacillus Calmette-Guérin (vaccine)
BL-3        biosafety level 3
CDC         Centers for Disease Control and Prevention (USA)
CDS         Communicable Diseases (WHO)
CRO         Contract Research Organization
CT B        B-Submit of Cholera Toxin
DC          developing countries
DT          diphtheria–tetanus (vaccine)
DTP         diphtheria–tetanus–pertussis (vaccine)
ETEC        Enterotoxigenic E-coli
GAVI        Global Alliance for Vaccines and Immunization
GMP         good manufacturing practice
HBV         hepatitis B virus
HepB        hepatitis B vaccine
Hib         Haemophilus influenzae type b
HIV         human immunodeficiency virus
IFN         Interferon
IVR         Initiative for Vaccine Research
MVA         Modified Vaccinia Ankara strain of vaccinia virus
NIH         National Institutes of Health (USA)
PATH        Program for Appropriate Technology in Health (USA)
PCR         polymerase chain reaction
pfu         plaque-forming units
QSB Quality Assurance and Safety of Biologicals
RSV respiratory syncytial virus
SAGE Scientific Advisory Group of Experts
SCUDDS Self-contained Unit Dose Delivery Systems
SOP standard operating procedure
TDR UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases
TT tetanus toxoid
UNAIDS Joint United Nations Programme on HIV/AIDS
UNDP United Nations Development Programme
V&B Vaccines and Biologicals (WHO)
VAM Vaccine Assessment and Monitoring (V&B/WHO)
VVM vaccine vial monitor
Executive summary
(prepared by Dr Rino Rappuoli)

Introduction

The Montreux meetings were initiated in 1996 by Dr Paul-Henri Lambert, who was then Head of the Vaccine Development Team of the Department of Vaccines and Biologicals. The first meeting, held before the Strategic Advisory Group of Experts (SAGE) had been formed, gathered technical information on the basis of which informed decisions and recommendations on vaccine development could be made. When the Global Alliance for Vaccines and Immunization (GAVI) came into the picture, the organization of the Montreux meetings was shared by WHO, which hosted them, and the GAVI Research and Development Task Force. The aim of the meetings is now to bring together the major players in vaccine development and implementation, to communicate and discuss the activities and strategies adopted by the Task Force, to explore what is new in the field, to find out which issues are open, and to make recommendations. The 2001 meeting was chaired by the industrial co-chair of the Research and Development Task Force, and its goal was to bring to the forefront all the problems that vaccine manufacturers were facing in developed and developing countries.

Introductory session

Following brief introductory remarks by Dr M. Teresa Aguado and Dr Rino Rappuoli, a keynote lecture was delivered by Dr Jacques-François Martin, President of the Vaccine Fund, an expert with extensive experience as a senior manager in the vaccine industry and with much recently acquired know-how in the public sector. Infectious diseases are the main reason for economic problems in the developing world. However, for the first time, the vaccine community is coming together in a true alliance (GAVI) in order to combat these diseases, even in the poorer countries. Within the alliance it is essential for the public and private sectors to collaborate with one another. Clearly, in order for this to be possible they have to understand each other. The private sector has to make a profit in order to be able to contribute financially to GAVI. Some vaccines are still perceived as a public benefit which ought to be inexpensive. It has to be realized, however, that they provide the best value in terms of medical intervention and that the appropriate price is not being paid for the service they represent.

The Global Fund was initiated by the generosity of Bill and Melinda Gates with a donation of US$ 750 million. This has encouraged further donations from other charitable organizations and from governments, taking the figure to $1.1 billion. The target for donations is 1.8 billion. Of these funds, $370 million has already been committed to the acquisition of products and $75 million has been dedicated to
infrastructural purposes. The week before the meeting the first immunizations with vaccines provided by the Vaccine Fund were given to children in Mozambique. Once vaccinated, they were given yellow vaccination cards as “passports for life”.

Brief addresses were given by Mr Michel Zaffran from WHO, replacing Dr Tore Godal, and by the Co-Chairmen of the GAVI Research and Development Task Force, Dr Yasuhiro Suzuki and Dr Myron Levine, who presented an update on GAVI activities and the progress of the Task Force. The following strategic objectives of GAVI are:

- improvement of access to immunization services;
- expansion of the use of existing cost-effective vaccines;
- acceleration of the development and introduction of new vaccines;
- acceleration of research and development efforts in respect of vaccines and related products specifically needed by developing countries, particularly vaccines against HIV/AIDS, malaria and tuberculosis;
- to make immunization an integral part of international development efforts.

It is advisable to consider this as an economical investment rather than as a charitable operation, and therefore attempts should be made to raise more money for the Vaccine Fund, possibly through G8 involvement, in order to increase the interest of the private sector in preventive vaccines. The private sector is actually shifting its attention from preventive to therapeutic vaccines, which are believed to be more profitable.

The mission of the Task Force is to catalyse action in research and development in support of GAVI’s overall objectives. In particular the Task Force should support the objectives of:

- accelerating the development and introduction of new vaccines and technologies;
- accelerating research and development work on vaccines needed primarily in developing countries.

In order to achieve these goals the Task Force had initially decided to focus on three specific projects and three new short-term technologies of high impact and high probability of success. Project selection was carried out by circulating a questionnaire and reviewing the responses at a meeting held in Boston in the autumn of 2000. The candidate vaccines considered in the questionnaire related to:

- HIV/AIDS
- Malaria
- Tuberculosis
- *Streptococcus pneumoniae*
- Rotavirus
The Task Force recognized that HIV, tuberculosis and malaria merited high priority. However, given the massive global effort that was involved in these projects, little could be done to push them any further at present. The Task Force also recognized that if suitable vaccines became available there was no infrastructure available to put them into efficient public health use. It was therefore decided to focus on vaccines of lower technical risk (e.g. where proof of concept had already been obtained). Success with these vaccines would alleviate the burden of important diseases in developing countries and would build the infrastructure for the efficient delivery of vaccines emerging later, such as HIV, tuberculosis and malaria vaccines. On the basis of all the relevant criteria it was recommended that the Task Force initially concentrate on vaccines against:

- *Neisseria meningitidis* group A (and C)
- *Shigella*
- Respiratory syncytial virus (RSV)

Once the groundwork is laid by work on these vaccines, attention could turn to the more difficult candidates such as HIV, malaria and tuberculosis vaccines. A process has been initiated for the selection of new technologies, focusing on those which would provide increased access to immunization, provide safety of vaccines and vaccination, and improved disease surveillance and management of immunization services.

The introductory session was concluded with presentations on the strategies and activities of the other GAVI task forces by Dr Amie Batson, Co-Chair of the Task Force on Financing, Ms Diana Chang-Blanc, Task Force on Country Coordination, and Dr Heidi Larson, Chair of the Task Force on Advocacy. Close collaboration and communication on the activities of the different task forces is necessary in order to maximize GAVI's overall impact.

Another important common goal of GAVI consists of finding mechanisms to encourage the private sector to invest in vaccines dedicated to the poorest countries.
World Health Organization and the Global Alliance for Vaccines and Immunization

Overall Chairperson: Rino Rappuoli

Moderators/Co-Chairpersons: Gus Nossal
Claire Broome
Mike Levine
Jan Holmgren
Gordon Dougan
Rosanna Lagos
Rino Rappuoli

Rapporteurs: Uli Fruth
Margaret Liu
Mark Miller
Giuseppe del Giudice
George Curlin
Howard Engers
Ron Dagan
Amie Batson

GAVI Representative: Tore Godal

WHO/IVR Representative: Teresa Aguado

Participants: See Annex 1
Progress towards vaccines for HIV/AIDS, malaria and tuberculosis: overview and highlights

HIV/AIDS: The biological basis of an AIDS vaccine
(Neil Nathanson and Donald Francis)

The difficulties facing the development of a vaccine against HIV/AIDS includes the biology of viral persistence and disease progression which is poorly understood. This is also true for the mechanisms of protection against infection and/or disease. It remains unclear whether a vaccine against HIV/AIDS should induce sterilizing or partial immunity, as existing vaccines usually provide only partial immunity. The immune correlates of protection against AIDS have not been defined, although it has been reported that protection is associated with the presence of antibodies, CD4+ proliferating cells, and/or CD8+ cytotoxic lymphocytes. The different findings could be explained by the utilization of different model systems and different immunization protocols. It remains entirely possible that a combination of the three effector systems would be ideal for the induction of vaccine-mediated protection.

Another crucial open issue relevant to the development of an effective AIDS vaccine concerns the intrinsic variability of the virus and the question as to whether clades, 10 at present, represent distinct immunotypes at the antibody and/or cellular level, or whether a “common” vaccine against HIV-1 is conceivable. Five groups have products in phase I trials, one group (priming with avipox expressing the gp120, followed by boosting with the recombinant protein) has a construct in phase II trials, and one group (VaxGen) is in phase III trials. Eighteen groups have products at the pre-clinical stage, more or less close to clinical trials. Promising data (significantly reduced viraemia, although without sterilizing immunity) are coming from studies pursuing the approach of priming with DNA and boosting with the same gene (gp120) expressed in MVA.

To summarize the outline of phase III trials currently in progress with the VaxGen vaccine, it contains gp120 protein adjuvanted with alum and has shown 100% protection in chimpanzees against a homologous challenge. In phase I/II trials the vaccine has demonstrated a very good safety profile and very good immune responses. The ongoing phase III trials are being conducted in the USA (B clade, infection rate 1.5% per year, 5400 individuals, 61 clinical sites) and Thailand (B/E clades, infection rate 6% per year, 2500 individuals, 17 clinical sites). The primary endpoint will be prevention of infection. The secondary endpoint will be the reduction of viraemia as measured by PCR. Safety, adverse events, behavioural changes, and potential correlates of protection will also be evaluated. An interim analysis of the study in the USA will be carried out in November 2001 and the study will be completed at the end of 2002. The interim analysis of the Thai study will be performed at the end of 2002 and this study will terminate in November 2003.
Malaria: Vaccines against blood stages of malaria parasites
(Chetan Chitnis)

*Plasmodium falciparum* causes 300–500 million cases of malaria and 1.5–2 million deaths annually, mainly in sub-Saharan Africa. *P. vivax* causes 75–90 million cases per year. Malaria is also appearing in non-immune migrant populations in Asia and South America. The frequency of drug-resistant strains of parasites is increasing worldwide, as is the resistance of mosquitoes vectors to insecticides.

Numerous obstacles hinder the development of a malaria vaccine. There are several species of parasite (*P. falciparum, P. vivax*, etc.) and multiple stages (liver, blood, sexual), which induce species and stage-specific immunity. It is not possible to culture *P. falciparum* in axenic conditions and *P. vivax* cannot be cultured at all. The predictability of animal models of infection with human malaria parasites is not well established. No correlates of protection have been defined and the malaria parasites have developed multiple immune evasion mechanisms (antigenic diversity, antigenic variation, etc.). Finally, the private sector has shown decreasing interest in the development of a malaria vaccine.

Nevertheless, several observations suggest that the development of a vaccine against malaria is conceivable.

At the International Centre for Genetic Engineering and Biotechnology (ICGEB) in New Delhi, research and development has focused on the merozoite surface antigen 1 (MSP-119) and on the erythrocyte-binding antigen 175 (EBA-175). MSP-1 is a highly variable 195 kDa protein expressed on the surface of merozoites. However, it contains a well-conserved C-terminal sequence (MSP-119) that may be a very promising candidate. EBA-175 in *P. falciparum* is the equivalent of the Duffy binding protein of *P. vivax*, which is considered as a candidate antigen for a vaccine against infection by *P. vivax*. The production of both recombinant proteins is now being scaled up.

Efforts are being concentrated on the identification of the best adjuvant or adjuvants to generate functional antibodies (e.g. QS21, MF59, Montanides, SBAS2, etc.) and on the evaluation of efficacy against *P. falciparum* challenge in Aotus monkeys, with a view to clinical trials in 2003. A potential field site for future vaccination trials has been identified in the Sundergarh District of Orissa. Transmission occurs throughout the year in this area; 96% of infections are attributable to *P. falciparum* and 2–3% to *P. vivax*; children aged 1–5 years experience multiple episodes annually; older individuals exhibit anti-disease immunity.

Malaria: Pre-erythrocytic malaria vaccines
(Adrian Hill)

Vaccination with irradiated sporozoites has been shown to protect mice, monkeys and humans (apparently through CD8 cytolytic T-cells), thus demonstrating that it is possible to eliminate the parasite at the time of infection. Challenge models are available in humans and small animals.
In the area of pre-erythrocytic malaria vaccines, two strategies have shown some protective efficacy in humans, both of them involving effector mechanisms mediated by T-cells. One consists of a protein-adjuvant vaccine (RTS,S antigen plus the SBAS2 adjuvant); the other involves DNA priming followed by boosting with the same gene expressed in MVA.

The RTS,S antigen is a fusion protein containing most of the CS protein of \textit{P. falciparum} and HbsAg. SBAS2 is a cocktail adjuvant containing MPL, QS21 and an oil-in-water emulsion; it induces good antibody and CD4 responses. In challenge experiments this vaccine protected six out of seven immunized volunteers. When the infectious challenge was repeated after six months however, only one in six remained protected. The overall efficacy of the vaccine in a homologous challenge model involving over 50 volunteers was 40–45%. In a phase IIb efficacy trial involving 306 volunteers in the Gambia, the efficacy against infection for the whole surveillance period was 34–71% during the first nine weeks but 0% for the following six weeks. A single booster dose produced 47% efficacy during the following malaria season. This vaccine induced high levels of cells producing IFN-gamma, but the duration of the T-cell response was short. Thus the RTS,S vaccine can induce cross-strain protection of limited duration. This vaccine is currently being improved by the addition of a blood-stage antigen (MSP-1).

The prime-boost approach developed by Adrian Hill's group uses non-replicating poxviruses to boost the cellular immune response primed with DNA. This approach is powerful for inducing proliferation of specific CD8 cells and for enhancing Th1-type CD4 cell responses. The modified vaccinia virus Ankara (MVA) is a highly attenuated vaccinia virus strain that replicates in chicken embryo fibroblasts but not in mammalian cells. More than 120 000 people have been vaccinated with non-recombinant MVA as a vaccine against smallpox with an excellent safety profile.

A DNA construct was produced which consisted of a polyepitopic sequence coding for several CD8 epitopes (with various HLA class-I restrictions) fused with the TRAP/SSP2 coding sequence. This construct was inserted into a plasmid for use as a DNA vaccine, as well as into the MVA vector. The DNA vaccine was then administered intradermally (500 micrograms) or using a PowderJect gene gun to volunteers in a phase I trial in the United Kingdom. An MVA boost was given intradermally. As in similar phase I trials in the Gambia, no safety issues were reported. Priming with the gene gun and boosting with MVA induced the best CD8 responses. DNA-MVA was more immunogenic than either alone. In a human challenge experiment in the United Kingdom, two of six volunteers immunized in accordance with this vaccination schedule exhibited a significant delay in the appearance of parasites in their bloodstream. T-cell responses were stronger in Africans than in non-immune Europeans. DNA-MVA clinical trials have started or will start soon in other disease models: HIV (United Kingdom and Kenya), tuberculosis (BCG priming + MVA-Ag85 boost, United Kingdom), hepatitis B (therapeutic, the Gambia). Work in progress aims at the optimization of dosage, route and intervals, as well as the evaluation of the replacement of DNA by fowlpox virus for the priming vaccination.
Other ongoing pre-erythrocytic malaria vaccine trials include: (i) five plasmids tested in up to 40 challenged volunteers with or without a plasmid coding for GM-CSF, United States Navy; (ii) phase I clinical trial with long CS peptides plus Montanide ISA 172 as adjuvant, University of Lausanne; (iii) phase I trial with long LSA-3 peptides plus adjuvant, Pasteur Institute.

**Tuberculosis: Tuberculosis vaccines** (Harriet Mayanja-Kizza)

Tuberculosis still causes high mortality and morbidity, especially in developing countries. The situation is worsened by the HIV epidemic and the emergence of multiple-drug-resistant strains of mycobacteria. Control measures include case-finding, treatment, environmental control and vaccination with BCG. BCG, which was introduced in 1921, provides reasonable protection against childhood manifestations of tuberculosis such as tubercular meningitis. However, it gives inadequate and inconsistent protection against cavitating pulmonary tuberculosis, with efficacy varying between 0% and 80%. BCG-mediated protection declines with the age at vaccination and no protection is seen in subjects older than 15 years, possibly because of interference with environmental mycobacteria to which older individuals are exposed.

The animal models (mice, guinea pigs, rabbits) available for testing new vaccines are not optimal and no precise surrogate of protection is currently available. Several approaches are being followed for the development of new vaccines against tuberculosis: (i) development of new attenuated strains of the pathogen, *Mycobacterium tuberculosis*; (ii) knock-in mutations of the current vaccine, BCG, to improve its immunogenicity; (iii) protein subunit vaccines with antigens such as MTB72, Ag85, fusion protein of Ag85 and ESAT-6, major secretory protein of 30 kDa; (iv) DNA vaccines have been tested in animals using the Ag85 as a model; (v) the same model has also been tested in the DNA prime/protein boost approach. The development of therapeutic vaccines is also being considered with a killed preparation of *M. vaccae*.

**Tuberculosis: Report on the Global Forum on Tuberculosis Vaccines Research and Development** (Mike Brennan)

Eight million new cases of tuberculosis are diagnosed every year, causing roughly 2 million deaths. Thus a vaccine with an effectiveness as low as 50% would save more than a million lives annually. The Global Forum on Tuberculosis Vaccines Research and Development was held in Geneva on 7–8 June 2001. It was recognized that the availability of at least 10 candidate tuberculosis vaccines for testing in humans represented a turning point in tuberculosis vaccine development. The clinical testing of tuberculosis vaccines will now be the driving force in this field.

A five-year action plan has been developed with the following milestones: (i) testing a minimum of five tuberculosis vaccines in phase I/II clinical studies; (ii) building a clinical site infrastructure to begin testing a minimum of one tuberculosis vaccine in phase III efficacy studies; (iii) standardizing and optimizing preclinical testing in animal models.
The following recommendations have been made.

A. For preclinical testing strategies:
   1. Standardize animal models for tuberculosis.
   2. Establish international testing centres with BL-3 capacity.
   3. Use animal models to test human infection and immunization paradigms, including latency and reinfection, dose and immunization schedules, development of potency assays, immunization strategies (e.g. prime-boost strategies, exposure to environmental mycobacteria, etc.).

B. For clinical trials:
   1. Establish a clinical trials network for tuberculosis vaccines.
   2. Establish an adult immunization strategy.
   3. Develop standardized guidelines for clinical evaluation of tuberculosis vaccines.
   4. Integrate new tuberculosis diagnostics into clinical studies.
   5. Synergize with other research programmes (e.g. tuberculosis drugs, tuberculosis diagnostics, AIDS, malaria).
   6. Address tuberculosis-specific issues, e.g. vaccines for tuberculosis-infected and BCG-immunized populations, populations with high incidence of AIDS.

C. For manufacturing:
   1. Partner academic vaccine developers with facilities capable of producing vaccine trial lots under GMP.
   2. Promote efforts to harmonize regulatory standards for tuberculosis vaccines.
   3. Address tuberculosis-specific issues, e.g. BL-3, manufacturing facilities, potency assays, safety studies.
   4. Perform vaccino-economic and cost-effectiveness analysis to assure global access to tuberculosis vaccines.
Pneumococcal vaccines (Orin Levine and Ron Dagan)

Pneumococci are the major causative organisms of invasive infections, bacterial pneumonia and acute otitis media. It is estimated that they cause annually over a million deaths in children under five years of age. Over 90 serotypes have been identified but a relatively small number of them account for most invasive disease. A 7-valent conjugate vaccine has been licensed. It has proved efficacious against invasive disease and bacterial carriage but less so against otitis media. 9-valent and 11-valent vaccines are at the phase III stage of development. The following questions have to be considered:

- Will the efficacy observed in developed countries be repeated in developing countries?
- Will the serotypes included in the vaccines be replaced by other serotypes?
- Will resistance increase in these serotypes?
- Will conjugate vaccines be available for poorer countries in the coming years?

One of GAVI’s objectives is to accelerate the introduction of pneumococcal conjugate vaccines. The Task Force on Research and Development met at NIH in April 2001, with representatives of industry, academia and regulatory agencies, in order to identify priority research and development activities on Pneumococcal Conjugate Vaccines necessary for accelerating the development and use of these vaccines. Among the activities identified the following were considered to be of the highest priority:

- development of methods to assess disease burden in various settings;
- standardization of diagnosis of pneumonia by X-ray;
- expansion of surveillance of laboratory-confirmed disease;
- measurement of pneumonia burden;
- establishment of long-term surveillance to measure vaccine impact;
- generation of more local advocacy from research.

The final document is not a comprehensive agenda of all research needs in pneumococcal diseases and vaccines. It includes only those high-priority activities that would lead to the development and introduction of conjugate vaccines in developing countries. However, it also acknowledges the importance of research in adults and on approaches other than that involving conjugate vaccines, such as the
use of protein vaccines, but goes not further on this subject. The process should see the involvement of the broad research and development community and coordination with other task forces and their communities.

**Rotavirus vaccines** (Roger Glass and Bernard Ivanoff)

Rotavirus is the most common cause of diarrhoeal deaths among children in developing countries and of diarrhoea leading to hospitalization worldwide. A vaccine licensed in the USA in 1998 was administered to over 800 000 children. Vaccine-associated intussusception was identified within nine months, the recommendation to use the vaccine was withdrawn, and production was stopped. The risk of intussusception being one event in 12 000 to 56 000 vaccinees, the first 800 000 vaccinees would have experienced 13 000 fewer diarrhoeal hospitalizations but 67 more intussusceptions (one per 200 rotavirus hospitalizations). In developing countries, rotavirus kills one child in 200. The risk of intussusception in these countries is unknown. However, assuming that the rates are similar to those observed in the USA, one vaccine-associated intussusception death would be expected for every 250 rotavirus deaths averted. The need for rotavirus vaccine in developing countries thus remains clear. Currently, two international vaccine manufacturers and two local producers are making and testing new rotavirus vaccines. It is necessary to establish the safety and efficacy of the next generation of rotavirus vaccines and to ensure their availability in adequate amounts and at an affordable price for children in developing countries. WHO has therefore made the following recommendations:

- The development of new candidate rotavirus vaccines should be encouraged.
- Parallel testing of new vaccines should be performed in developed and developing countries.
- The potential risk of intussusception should be assessed.
- Research on the pathogenesis and epidemiology of intussusception should continue, especially in countries interested in testing new rotavirus vaccines.
- Studies on the rotavirus disease burden should be performed in selected developing countries.
- Laboratory surveillance of rotavirus strains should continue, especially in Africa and Asia.

WHO has already initiated several of these activities.

**Meningococcal vaccines** (Luis Jodar)

A substantial reduction of meningitis-associated mortality and morbidity could be achieved in Africa by the introduction of group A/C conjugate vaccines. Several companies suspended development of these vaccines during the 1990s because of high costs and insufficient returns. GAVI has sought to develop a tailor-made vaccine for Africa through the Meningitis Vaccine Project, which foresees public-private partnerships and detailed analysis of costs and timelines. In order to stimulate industrial interest the Project envisages capital investment for production capacity, support for clinical activities, support for a fast-track licensing strategy, and guaranteed purchase. The future activities will include:
• Appointing a director and staff.
• Negotiating partnership agreements.
• Making site visits to companies.
• Making a presentation to GAVI.
• Holding meetings for strategy development with African countries.
• Formulating an implementation plan with partners.

The prevention of meningococcal epidemics is a matter of high priority for the countries in the African meningitis belt. Conjugate vaccines could prevent and eventually eliminate these epidemics. The introduction of conjugate A or A/C vaccine is feasible and affordable in the short-term. The potential exists for strengthening immunization services, achieving sustainability and synergizing with other disease control programmes. The Project could become a model for public-private sector partnerships in respect of other “orphan” vaccines.
New immunization technologies

A process for identifying and selecting new technologies
(Teresa Aguado and Peter Wilson)

The objective was to select up to three new technologies capable of improving safety, compliance and effectiveness in immunization. By early 2002 the GAVI Task Force on R&D will make recommendations on the selected technologies.

New technologies cover a wide range of possible applications and are at various stages of development. For the purpose of ranking a list of these technologies was prepared and some 65 questionnaires were distributed in developed and developing countries. The questions, suggested by the Research and Development Task Force, were as follows:

- How can new technologies or research improve immunization?
- What are the criteria for selection?
- What is the prioritization of the broad technology/research areas?
- How are specific technologies/research identified and prioritized?

Of the 41 responses analysed, 12 came from developing countries and four from industry. The responses gave the following clear indications.

- There is a desire to make immunization simpler and easier by reducing the number of patient interactions, improving management and tracking systems, and solving short-term engineering problems (e.g. in the cold chain).
- Dependency on the cold chain, which appeared to be a major source of difficulty, should be reduced.
- The use of sharps should be reduced in the long term and there should be a move to non-parenteral immunization.
- New ways of making immunization safer should be investigated.
- There is a need to understand the effectiveness of the immunization service and factors affecting access to and coverage of immunization, with a view to achieving improvement in these matters.

Three study teams have been set up on safety (e.g. administration, risks of contamination), efficiency (e.g. reduction of wastage, reduction of dependency on the cold chain, reduction of contacts, use of multidose/multivalent vaccines) and effectiveness (e.g. access, coverage, practical engineering problems, logistics).
These teams are expected to perform the synthesis necessary for recommendations to be made to the GAVI Board. The major tasks of the study teams are: to define goals and criteria of success; to identify the main issues and constraints; to review alternative strategies for achieving goals and addressing the issues (short term and long term); to identify technologies or research areas critical for success; to identify how new technology can be applied to a particular vaccine project; and to evaluate and recommend specific technologies and research.

**Priority area: assuring safe and effective vaccine administration**  
(Michael Free)

Current challenges in immunization include unsafe administration, wasted vaccine, spoiled vaccine, decaying cold chain, inaccurate dosing, syringe shortages, poor infrastructure, outreach, and addition of new vaccines. Various means are available for assuring safe and effective vaccine administration. They include: detection and prevention of heat damage and freeze damage, the prevention of vaccine contamination, provision of means of administration, provision of sterile administration and correct doses, and prevention of collateral sharps injury.

Heat damage is monitored with vaccine vial monitors (VVMs). First used for OPV, VVMs are now available for most vaccines and have also been accepted by WHO, GAVI and UNICEF as a means of reducing vaccine wastage. The prevention of heat damage, i.e. the improvement of vaccine stability, can be achieved by glassification (using sugar stabilizers such as trehalose), which has been successfully tested with measles vaccine, DT and DTP. Other systems for preventing heat damage include fail-safe refrigeration systems, spray-drying (for dry injection or inhalation), and cochleation (for oral delivery). The prevention of freeze damage is critical for hepatitis B vaccine (HepB), DTP, TT and other vaccines. This can be achieved by means of freeze indicators, although this technology is only applicable to batches, i.e. not to individual vials.

The contamination of vaccines can be prevented by using monodose vaccines (however, this increases costs and volumes), auto-disable reconstitution syringes (plastic needles), and auto-reconstitution (enables storage as stabilized dry vaccine). Reusable administration systems are frequently associated with the transmission of HBV infection (30% risk). Disposable administration systems assure sterile injections with auto-disable syringes, self-contained unit dose delivery systems (SCUDDS, such as UniJect™). Collateral sharps injuries can be prevented by needle-free administration (jet injector, needle-free SCUDDS).

With a view to assuring safe and effective vaccine administration the GAVI research and development agenda may include the following.
For the short term, i.e. under 5 years:

- Roll-out of VVMs for all vaccines, monodose vials, auto-disable syringes for routine use, injection SCUDDS, campaign jet injectors.
- Validation of high-efficiency refrigerator, ice-free cooling, out-of-the-cold vaccines, sharps disposal solutions.
- Development of sugar/glass stabilizers, injection SCUDDS, reconstitution auto-disable syringes.

For the long term, i.e. 5–10 years:

- Research and development on auto-reconstitution systems, non-invasive SCUDDS, other stabilization systems (for new vaccines).

**Priority area: systems efficiency** (Gordon Dougan)

The aim of improving vaccine efficiency is to reduce the morbidity and mortality burden of infectious diseases as safely and cheaply as possible. Systems efficiency can work at many levels against a background of improvements in safety and programme effectiveness.

The first area relates to the stability of vaccines, with reference to both shelf-life and field-life. This can be achieved through the stabilization of the vaccine preparation. Examples of these systems are lyophilization, glass technology (which still requires validation by using a single vaccine such as TT), and slow-release methods (which also require validation).

The second area relates to the enhancement of immunogenicity, with the final objective of reducing the number of contacts. This can be achieved by means of better adjuvants and immunostimulators, slow-release systems such as biodegradable particles, and better delivery systems such as guns, inhalers, and DNA versus protein. It is still undecided as to what impact the combination of strong adjuvants would have.

The third area relates to the safe delivery mode of vaccines, in terms of guns, sprays, patches, etc., via the mucosal, oral, nasal and transcutaneous routes. Little is known about the latter in humans with respect to safety, mechanisms and immunogenicity, and short-term validation is required (phase I and II trials). Mucosal delivery has produced a large volume of scientific literature but few potential products because of the need for the optimization of improved formulations and delivery systems.

The current needs for systems efficiency are as follows:

- For stabilization: glass/sugar stabilizers and others.
- For immunogenicity: improved adjuvants, impact on combination of strong adjuvants.
- For delivery: non-invasive delivery (devices, transcutaneous), devices for gut and nose delivery (possibly SCUDDS), studies in humans (adjuvants/formulations), geographical differences in responsiveness.
Priority area: programme effectiveness (Rosanna Lagos)

The main goal is to evaluate the effectiveness of immunization services in a manner which is accurate, sustainable and synergistic with other public health interventions. This requires competent management, accurate monitoring of achievements, and safe and efficient immunizations.

How can the efficiency of immunization services at the operational level be improved? Immunization services are very efficient in urban areas, with up to ten immunization contacts and vaccination records per hour. In rural areas, however, reaching a handful of children may involve expensive logistical arrangements and costs are therefore much higher than in cities.

Technologies are needed for: (i) assessing the costs of immunization services; (ii) information systems for monitoring vaccination at the level of the individual vaccine; (iii) information systems for assessing impact on diseases; (iv) reliable and easy evaluation of immune protection.

In order to improve the effectiveness of immunization at the operational level, great importance is attached to reducing the number of immunizations, dependence on the cold chain, wastage and contamination.
New developments in selected areas

*Shigella vaccines* (Karen Kotloff)

Shigellosis affects more than 160 million people and causes 1.2 million deaths every year. It is highly contagious, oral rehydration provides little benefit, and antibiotic resistance is increasing. Several studies in human volunteers have shown that the use of vaccines against shigellosis is feasible. Parenteral conjugates, nasal proteosomes and invasive live attenuated deletion mutants are being tested. Some of these vaccines, especially a live oral attenuated vaccine, have shown promising efficacy against challenge in volunteers. However, recent results from phase I/II trials in children are less promising. Because of serotype specificity in protection, a multivalent *Shigella* vaccine approach is being pursued with a cocktail of *Shigella* species carrying appropriate gene mutations.

*ETEC* (R. Abu-Elyazeed)

Enterotoxigenic E-coli remains a leading cause of diarrhoea in developing countries and travellers. An oral vaccine consisting of killed whole-cell ETEC plus recombinant CT B subunit has shown promise in adult volunteers. This vaccine had proved very safe and strongly immunogenic among adults and young persons in trials conducted in developed and developing countries. Efficacy trials of the vaccine are now in progress in the Nile Delta region in Egypt among children aged 6–18 months. Data on the trial will be available by early 2002.

*RSV* (Theodor Tsai and Eric Simoes)

RSV infects 90% of children by 2 years of age and causes lower respiratory tract disease in children aged up to 5 years. The most severe cases occur in infancy, especially in children aged under 6 months. RSV accounts for between 250 000 and 900 000 deaths annually in children over 5 years of age. Passive immunization with specific intravenous immunoglobulins has reduced RSV hospitalization by about 50%. The development of a vaccine has met several obstacles, the most significant deriving from the observation that formalin-inactivated vaccine enhanced lung pathology and mortality during the 1960s.

Several RSV subunit vaccines are now under development, involving fusions of both recombinant F or G proteins or fusions of parts of them. These vaccines have been shown to be efficacious in animal models and safe in humans in phase I/II trials. Cold-adapted mutants of the virus have been obtained and used for intranasal delivery. In humans these strains have shown acceptable safety.
New adjuvants

CpGs (Heather Davis)

CpG motifs are unmethylated C-G dinucleotides in a particular base context. They strongly stimulate innate immunity. In microorganisms, C-G dinucleotides are expected at a random frequency of one in every 16 base pairs. In vertebrates their frequency is suppressed from one-third to one-fourth. In mammals, C residues are highly methylated and thus lose their immunostimulating properties. Acting through Tol Receptor-9, CpG motifs stimulate a variety of immune cells. This stimulation includes: (i) direct activation of B-cells; (ii) direct activation of macrophages and dendritic cells; (iii) activation of NK cells; (iv) activation of CD4+ and CD8+ cells, leading to the development of an immune response of the Th1 type. CpG motifs augment adaptive immune responses and have proved superior to well-known adjuvants in the induction of Th1-biased immune responses. The adjuvanticity of CpG motifs has been demonstrated in monkeys through the use of hepatitis B vaccine. In phase I trials in humans with CpG-adjuvanted hepatitis B vaccine, a strong and early vaccine-specific immune response has been induced. Further pre-clinical studies have indicated the potential use of CpG as an adjuvant for a variety of vaccines.

MF59 (Giuseppe Del Giudice)

MF59 is an oil-in-water emulsion containing squalene, Tween-80 and other components. Although the exact mechanisms of adjuvanticity are not known, it seems to work through the activation of antigen-presenting cells. In mice, MF59 has shown strong adjuvanticity for influenza vaccines, enhancing the immune responses in old animals at levels normally encountered in young individuals. MF59 appears to induce a pronounced immune response of the Th2 type. Extensive clinical data demonstrate that MF59 strongly enhances the immune response to influenza vaccine in older individuals. On the basis of these data the MF59-adjuvanted influenza vaccine was licensed in Europe in 2000. This was the first adjuvant to be admitted for human use after alum. More recently, MF59 has significantly improved the immunogenicity of a vaccine against a pandemic strain of influenza virus and reduced the amount of antigen required to achieve protection. Similarly, MF59-adjuvanted hepatitis B vaccine has shown induced protective immunity in human volunteers after two doses of the vaccine, instead of the usual three.

Virosomes (Reinhard Glück)

Virosomes are spherical vesicles with a diameter of 140 nm. They have been used to formulate hepatitis A and influenza vaccines and are licensed in various European countries. A virosomal influenza vaccine adjuvanted with wild-type Escherichia coli enterotoxin (LT) has been licensed in Switzerland for intranasal delivery. It was shown to be safe and efficacious in several animal models and shows good immunogenicity in humans.
Clinical trials

Scientific considerations on quality, safety and regulatory issues for vaccines under development: HIV as a model
(Elwyn Griffiths and José Esparza)

Many new vaccines are under development for several priority infections. Some approaches are following traditional lines, while others are moving into novel biotechnologies. It is essential that early consideration be given to regulatory issues associated with these products so as to ensure that safety and quality control are adequately addressed and that regulatory decisions have the soundest possible scientific basis worldwide. This should facilitate the licensing process and minimize delays in product availability.

Historically, assuring the consistent safety and efficacy of vaccines has been primarily a problem-led exercise, i.e. major problems have led to improvements in quality control procedures. In the biotechnology field, however, guidelines on production and control have been laid down early in the development of new products and have been instrumental in establishing their safety and quality, have assisted national regulatory authorities to regulate them successfully, and have facilitated the rapid introduction of new products into mainstream clinical use. With respect to vaccines, WHO guidelines have been developed for some novel technologies, e.g. for DNA and peptide vaccines. In order to develop an international consensus on safety and quality control in new vaccines, however, it is necessary to identify the issues so that they can be adequately addressed by the time of clinical trials and license application. Agreement is also required on criteria for vaccine efficacy and it is necessary to develop procedures for ensuring comparability in the measurement of potential correlates of protection and for providing adequate regulatory oversight.

The development of HIV vaccines provides a model for addressing such considerations. There is an intense public health interest in developing safe and effective preventive HIV vaccines because, as yet, there is no definite cure for AIDS. HIV vaccines represent the best long-term hope for controlling the HIV/AIDS epidemic, especially in developing countries, but their development presents unique and complex scientific, social, ethical and economic challenges.

A consultation on “Scientific considerations for evaluation of HIV vaccines and related regulatory perspectives”, organized by the Quality Assurance and Safety of Biologicals Team and the WHO/UNAIDS HIV Vaccine Initiative was held in Geneva on 13–16 March 2001. The principal recommendations that emerged are indicated below:
• HIV vaccine trials should be conducted only in countries with adequate regulatory resources; specific support for strengthening such resources should be sought where they are limited.

• Because of the use of several novel biotechnology approaches for vaccine production, new ways should be sought to provide appropriate specialized scientific support for national regulatory authorities of developing countries in the evaluation of candidate vaccines and clinical trial protocols and in licensing, in addition to the strengthening of regulatory processes.

• Criteria for vaccine efficacy should be clearly defined (prevention of infection, reduction of viral load) and it should be recognized that end-points may vary between countries.

• Because the production of some HIV vaccines raises issues about cell substrates which are not described in current regulatory guidelines, regulatory research should be conducted with a view to the development of further guidance based on sound science rather than on conjecture.

• Generic or specific guidelines on HIV vaccines delivered using viral and bacterial vectors should be developed.

• Consensus should be sought on methods for determining serological and cellular immune responses to HIV vaccines, as well as virus load, and appropriate reference materials should be developed for assay standardization at the international level in order to achieve global comparability of data.

• The WHO/UNAIDS Network for HIV Isolation and Characterization should be further developed in response to the continued spread of HIV, and molecular, biological and immunological information on incident viruses should be disseminated in a timely manner.

**Issues in clinical trials** (Mike Levine)

Dr Levine highlighted some principles and issues concerning bioethical, regulatory, design and financial aspects of clinical trials.

1. **What is the impetus for organizing large-scale vaccine field trials?**

Field sites generally fall into one of the following two categories.

• Site seeking a vaccine to test: A health ministry, contemplating vaccination as a future means of controlling disease, seeks one or more candidate vaccines for evaluation, e.g. the typhoid vaccine sought by Chile.

• Site sought by a vaccine developer: A vaccine developer seeks an appropriate site where the safety, immunogenicity and efficacy of a vaccine can be tested, e.g. cholera vaccines were developed and a site for testing them was subsequently sought.

2. **Who should finance large-scale phase III vaccine field trials?**

• Industry finances clinical development and large-scale trials for industrialized market vaccines and global market vaccines, a return being expected on this investment, e.g. initial Hib vaccine studies, Lyme disease vaccine.
• Public sector should support trials of developing market vaccines, e.g. asexual-stage malaria, typhoid, cholera, leishmaniasis.
• Public-private partnerships should foster trials of global market vaccines in developing countries, e.g. Hib, pneumococcal conjugates, rotavirus.

3. Several ethical issues in vaccine efficacy trials in developing countries:
• What control preparation should be used? This could be chosen on the basis of technical or ethical aspects, e.g. what is the standard of care?. The control preparation might be a true placebo; a licensed vaccine against another infection that can have no effect on the outcome events of the study, providing a benefit for control subjects (however, it is sometimes difficult to find a suitable vaccine which does not compromise double blindness of the trial).
• An experimental vaccine against another infection that has no effect on the outcome of the study.
• The cross-cultural complexities of informed consent should be recognized.
• Vulnerable populations, e.g. incarcerated individuals or poor populations receiving health services from the source responsible for the trial.
• What should be the responsibilities of the sponsor after the trial ends? Do they concern the study population and the larger reference population of the country or region in question. This issue should be discussed before the study is initiated.

4. Study design - reasons to randomize by units other than individual subjects:
• Nature of the vaccine, e.g. live vaccine with potential for person-to-person transmission, or vaccine conferring protection at the community level, as with transmission-blocking malaria vaccine.
• Logistics and practicality.
• Attempt to measure herd immunity.

5. Other issues in the design of various efficacy trials: who should decide when to stop a trial and break the code: industrial sponsors, who generally want to stop at the earliest possible time, or public health authorities, which generally prefer that a trial should run for an extended period of follow-up in order to obtain data on the duration of vaccine efficacy.

6. Strengthening the infrastructure in order to support large-scale vaccine field trials in developing countries; the microbiological infrastructure has to be strengthened, e.g. automated blood culture in children in preparation for pneumococcal vaccine trials. The health care delivery infrastructure often has to be reinforced as well.

7. Good clinical practices (GCP): Comprehensive regulations and guidelines on the conduct of clinical trials have to be followed if the results are to be included in an application for the licensing of a vaccine. They cover protocol design, record-keeping, laboratory standard operating procedures (SOPs), informed consent, data-reporting, and the reporting of adverse events.
8. Unexpected morbidity and mortality detected during efficacy trials. Trials should be examined carefully for unexpected events. Well-known examples include a phase III trial of formalin-inactivated RSV vaccine – where increased incidence of severe RSV disease in vaccinees vs. controls was observed; phase IV immunogenicity trials of high-titre measles vaccine (= 10^5 pfu) in young African and Haitian infants – increased long-term mortality in females.

9. The complexity of record-keeping, data management and formal randomization procedure is growing, e.g. increasing automation, remote data entry. This creates a tension between efforts to validate collected data and laboratory data (high-quality data) on the one hand and the simplification and economization of clinical trials on the other. Consequently, there has been a growth of contract research organizations (CROs). Among the most important roles of CROs in large trials are the management of data files, the random allocation of subjects to experimental vaccine or control regimens, and assisting in surveillance for serious adverse events. Unfortunately, CROs become very costly.

10. Efficacy versus effectiveness of vaccines. This issue is extremely important. Dr Levine believes that postlicensing effectiveness studies are of great value in helping towards understanding vaccine impact.
Views of industry and economic incentives for vaccine development

Manufacturers in developed countries (Michel Greco)

Dr Greco presented the views of the vaccine manufacturers of developed countries. He summarized the vaccine development process and showed that the research phase cost approximately 10% of the total budget necessary for the development of a vaccine. The early development phase accounted for approximately 20% of the costs, and 70% of the budget was required for the late development phase and registration.

Industry thus has selected projects very carefully before embarking on the development phase. The criteria used for selection include scientific and industrial feasibility combined with anticipation of an appropriate return on investment, which is usually calculated in relation to sales in developed countries only.

The vaccine industry is willing to help to achieve GAVI’s objectives in making vaccines available to developing countries at a lower price on the following conditions:

- The industry has to obtain most of the expected return from sales to the industrialized world.
- Products sold only in the developing world have to generate a reasonable profit.

This implied that dual pricing should not lead to price decreases in developed countries and that the protection of intellectual property should be enforced.

The push-and-pull mechanism could be an incentive to manufacturers to conduct research and develop and to supply vaccines that might not otherwise be available, as it will provide additional resources for vaccine development (push) and create a more visible market downstream (pull). Other mechanisms for encouraging the vaccine industry involves supplying epidemiological data, strengthening local clinical development infrastructures, creative regulatory support, vaccine advocacy, good estimation of the capacity needed for developing markets, and commitment to purchase.

Manufacturers in developing countries (Isais Raw)

On 18 April 2001, 18 public and private laboratories in developing countries had organized a meeting under WHO auspices in order to establish a network of vaccine manufacturers in these countries. The network aims at sharing bulk vaccines stocks and exchanging knowledge on technology, research and development. Manufacturers in developing countries already supplied EPI vaccines to half of the world and they intend to play an increasing role in GAVI activities.
The European Union: a new supporter of GAVI's activities
(Arnd Hoeveler)

Dr Hoeveler reported that the European Union had decided to support the fight against HIV/AIDS, malaria and tuberculosis in developing countries, with the aim of reducing poverty.

In addition to over 100 million Euros spent in support of research on the three diseases, a major new activity planned by the European Union involves the development of a clinical trials platform for developing countries. This infrastructure will be of value when candidate vaccines became available.
Annex 1:
List of participants

Dr Mohamed A. Abbadi, Chief Executive Officer, Vacsera Egyptian Organization for Biological Products and Vaccines, 51 Wezaret El Zeraa Street, Agouza, Giza, Egypt
Tel.: +20 2 336 9872; Fax: +20 2 748 3187
Email: m_abadi@hotmail.com

Dr Remon Abu-Elyazeed, US Naval Medical Research Unit No. 3, PSC 452 Box 5000, FPO AE 09835 0007
Tel.: +20 2 684 1375, Ext. 51 or 59; Fax: +20 2 684 1382
Email: AbuElYazeedR@namru3.med.navy.mil

Dr Francis André, Vice-President, Senior Medical Director, GlaxoSmithKline Biologicals, Rue de l’Institut 89, B-1330 Rixensart, Belgium
Tel.: +32 2 656 83 35; Fax: +32 2 656 90 58
Email: francis.andre@sbbio.be

Dr Zhi-Sheng Bai, Lanzhou Institute of Biological Products (GSKB), 118 Yanchang Road, Lanzhou, Gansu Province 730046, People’s Republic of China
Tel.: +86 931 836 8311; Fax: +86 931 834 3199
Email: baizs@public.lz.gs.cn

Ms Amie Batson, Health Specialist, Health and Development Network, The World Bank, 1818 High Street NW, Room G 3021, Washington DC 20433, USA
Tel.: +1 202 458 8300; Fax: +1 202 522 3489
Email: abatson@worldbank.org

Dr Sujit Bhattacharya, Director, National Institute of Cholera and Enteric Diseases, P-33 CIT Road, Scheme XM, Beliaghata, P.O. Box 177, Calcutta 700 010, India
Tel.: +91 350 1176; Fax: +91 350 5066
Email: bsandip@cal3.vsnl.net.in

Dr Fred Binka, School of Public Health, University of Ghana, P.O. Box 13, Legon, Ghana
Tel.: +233 21 401550; Fax: +233 21 500388
Email: fbinka@africaonline.com.gh

Dr Claire Boog, Deputy Head, Laboratory for Vaccine Research, National Institute of Public Health and the Environment (RIVM), Antonie van Leeuwenhoeklaan 9, P.O. Box 1, NL-3720 BA Bilthoven, Netherlands
Tel.: +31 30 274 2096; Fax: +31 30 2744429
Email: c.boog@rivm.nl
Dr Claire V. Broome, Deputy Director, Centers for Disease Control and Prevention (CDC), 1600 Clifton Road, N.E., MS D14, Atlanta, GA 30333, USA
Tel.: +1 404 639 7000; Fax: +1 404 639 7111
Email: cvb1@cdc.gov

Dr Margaret Burgess, Professor of Paediatrics and Child Health, University of Sydney, The Children's Hospital at Westmead, Locked Bag 4001, Westmead NSW 2145, Australia
Tel.: +61 2 98 45 30 69; Fax: +61 2 9845 30 82
Email: margarb1@chw.edu.au

Dr Anil Chawla, Panacea Biotec Ltd., A-241, Okhla Industrial Area-I, New Delhi, 110020, India
Tel.: +91 11 6813894; Fax: +91 11 6811140
Email: panacea-vaccine@id.eth.net

Dr Chetan Chitnis, International Centre for Genetic Engineering and Biotechnology, P.O. Box 10504, Aruna Asaf Ali Marg, New Delhi 110067, India
Tel.: +91 11 618 7695; Fax: +91 11 616 2316
Email: cchitnis@icgeb.res.in

Mr Young Hyun Cho, General Manager, Pharmaceutical Division, LG Chem Investment Ltd., LG Twin Tower 25th Fl., 20, Yoido-dong, Youndungpo-gu, Seoul 150 721, Republic of Korea
Tel.: +82 2 3773 0617; Fax: +82 2 785 0324
Email: yhcbob@lgci.co

Dr Michael Clark, Director, Discovery Portfolio, Strategic Planning and Epidemiology, GlaxoSmithKline Biologicals (GSKB), Rue de l’Institut 89, B-1330 Rixensart, Belgium
Tel.: +32 2 656 9311; Fax: +32 2 656 8127
Email: michael.j.clark@sbbio.be

Dr John Clemens, Director, International Vaccine Institute (IVI), Seoul National University Campus, Shillim Dong, Kwanak-ku, P.O. Box 14, Seoul 151 600, Republic of Korea
Tel.: +82 2 872 2801; Fax: +82 2 872 2803
Email: jclemens@ivi.int

Dr George T. Curlin, Acting Director, National Institute of Allergy and Infectious Diseases, Division of Microbiology and Infectious Diseases, National Institutes of Health, 6700-B Rockledge Drive – Room 3143, Bethesda, MD 20892, USA
Tel.: +1 301 496 3893; Fax: +1 301 480 4528
Email: gc24a@nih.gov

Dr Ron Dagan, Director, Soroka Medical Centre, Paediatric Infectious Disease Unit, P.O. Box 151, Beer Sheva 84101, Israel
Tel.: +972 8 640 05 47; Fax: +972 8 623 2334
Email: rdagam@bgumail.bgu.ac.il

Dr Heather Davis, Coley Pharmaceutical Canada, 11 Holland Avenue, Suite 608, Ottawa, Ontario, K1Y 4S1, Canada
Tel.: +1 613 761 94 54, Ext. 120; Fax: +1 613 761 86 61
Email: hdavis@coleycanada.com
Dr Jorge Dominguez, National Sales Manager, Laboratorios de Biológicos y Reactivos de México (Birmex), Amores 1240, Col. Del Valle, C.P. 03100, Mexico
Tel.: +54 22 28 44; Fax: +54 22 28 81
Email: jdominguezo@prodigy.net.mx

Dr Gordon Dougan, Imperial College of Science, Technology and Medicine, Department of Biochemistry, Exhibition Road, GB-London SW7 2AY, United Kingdom
Tel.: +44 207 594 5256; Fax: +44 207 594 5255
Email: g.dougan@ic.ac.uk

Dr Krishna Ella, Bharat Biotech International Ltd, 726 Venkateswara Hills, Road #3, Banjara Hills, Hyderabad 500 034, India
Tel.: +91 40 335 6388; Fax: +91 40 335 0344
Email: ellakrishna@yahoo.com

Dr Donald P. Francis, President, VaxGen, Inc., 1000 Marina Blvd, Second Floor, Brisbane, CA, USA
Tel.: +1 650 624 1027; Fax: +1 650 624 1019
Email: dfrancis@vaxgen.com

Dr Michael J. Free, Vice-President and Senior Adviser for Technologies, Program for Appropriate Technology in Health (PATH), 4 Nickerson Street, Seattle, Washington 98109-1699, USA
Tel.: +1 206 285 3500; Fax: +1 206 285 6619
Email: mfree@path.org

Mr Andrew Gengos, Vice-President and Chief Financial Officer, Dynavax Technologies Corp., 717 Potter Street, Suite 100, Berkeley, CA 94710, USA
Tel.: +1 510 430 7108; Fax: +1 510 430 7741
Email: agengos@dvax.com

Dr Giuseppe del Giudice, Chiron, Divisione Biologici et Farmaceutici, via Fiorentina 1, I-53100 Siena, Italy
Tel.: +39 05 77 24 32 61; Fax: +39 05 77 24 35 64
Email: giuseppe_del_giudice@chiron.it

Dr Roger Glass, Centers for Disease Control and Prevention, Viral Gastroenteritis Unit (G04) 1600 Clifton Road, Mailstop C19, Atlanta, GA 30333, USA
Tel.: +1 404 639 3577; Fax: +1 404 639 3645
Email: rglass@cdc.gov

Dr Reinhard Glück, Head of Research and Development, Swiss Serum and Vaccine Institute Bern, P.O. Box 3001, CH-Bern, Switzerland
Tel.: +41 31 888 5320 ; Fax: +41 31 888 5181
Email: reinhard.glueck@berna.org

Dr Michel Greco, President and Chief Operating Officer, Aventis Pasteur, Campus Méridieux, 2 avenue Pont Pasteur, F-69367 Lyon Cedex 07, France
Tel.: +33 4 37 37 77 68; Fax: +33 4 37 37 79 85
Email: mgreco@fr.pmc-vacc.com
Dr Gerardo Guillén, Director de Investigaciones Biomédicas, Centro de Ingeniería Genética y Biotecnología, Avenida 31 entre 158 y 190, Cubanacan, Apartado 6162, La Habana, Cuba  
Fax: +53 7 214764/33 7 336008  
Email: gerardo.guillen@cigb.edu.cu

Dr Jan Hendriks, Senior Adviser, International Health Programmes, National Institute of Public Health and the Environment (RIVM), Bureau for International Cooperation, Antonie van Leeuwenhoeklaan, 9, P.O. Box 1, NL-3720 BA Bilthoven, Netherlands  
Tel.: +31 30 274 2038/2694; Fax: +31 30 274 4405  
Email: j.hendriks@rivm.nl

Dr Luis Herrera Martínez, Director-General, Centro de Ingeniería Genética y Biotecnología, Avenida 31 entre 158 y 190 Cubanacan, Playa, P.O. Box 6162, 10600 Habana, Cuba  
Tel.: +53 7 21 6013/6613; Fax: +53 7 21 8070  
Email: Luis.Herrera@cigb.edu.cu

Dr Adrian Hill, University of Oxford, Molecular Immunology Group, Institute of Molecular Medicine, John Radcliffe Hospital, GB-Oxford OX3 9DS, United Kingdom  
Tel.: +44 1865 222301; Fax: +44 1865 221921  
Email: adrian.hill@imm.ox.ac.uk

Dr Arnd Hoeveler, European Commission, DG8, Rue de la Loi 200, B-1049 Bruxelles, Belgium  
Tel.: +32 2 295 68 01; Fax: +32 2 295 53 65  
Email: arnd.hoeveler@cec.eu.int

Mr Kyung Ho Kim, Green Cross Vaccine Corp. (6th Floor), 303 Bojung-Ri, Gusung-Myun Yongin-Si, Kyunggi-Do 449-910, Republic of Korea  
Tel.: +82 31 260 9547; Fax: +82 31 260 9400  
Email: ktkim1@greencrossvaccine.com

Professor Jan Holmgren, University of Göteborg, Department of Medical Microbiology and Immunology, Box 435, S-40530 Göteborg, Sweden  
Tel.: +46 31 342 4911; Fax: +46 31 82 01 60  
Email: jan.holmgren@microbio.gu.se

Dr Akira Homma, Vice President of Technology, Oswaldo Cruz Foundation, Av. Brasil 4.365 – Manguinhos, Rio de Janeiro, Cx. Postal 926 – CEP 21045-900, Brazil  
Tel.: +55 21 390 3114; Fax: +55 21 260 6707  
Email: homma@netra.castelo.fiocruz.br

Dr Anders Kärnell, Medical Director, SBL Vaccin, S-105 21 Stockholm, Sweden  
Tel.: +46 8 7351172; Fax: +46 8 834174  
Email: anders.karnell@sblvaccin.se
Dr Wenceslaus Kilama, Chairman, African Malaria Vaccine Testing Network, Tanzania Commission for Science and Technology, Building C26/27, Ali Hassan Mwinyi Road, P.O. Box 33207, Dar-Es-Salam, United Republic of Tanzania
Tel: +255 22 700018; Fax: +255 22 700380
Email: wkilama@africaonline.co.tz

Professor Karen L. Kotloff, Chief, Domestic Epidemiological Studies Section, University of Maryland School of Medicine, Center for Vaccine Development, 685 West Baltimore Street, Baltimore, MD 21201, USA
Tel.: +1 410 706 5328; Fax: +1 410 706 6205
Email: kkotloff@medicine.umaryland.edu

Dr G.R. Kumraj, Panacea Biotec Ltd., A-241, Okhla Industrial Area-I, New Delhi, 110020, India
Tel.: +91 11 6813894; Fax: +91 11 6811140
Email: panacea-vaccine@id.etb.net

Dr Rosanna Lagos, Hospital Roberto del Rio, Centro para Vacunas en Desarollo, Hospital de Niños, Roberto del Rio, Santiago, Chile
Tel.: +56 2 737 5022 ; Fax: +56 2 777 5766
Email: rlagos@adsl.tie.cl

Dr Paul-Henri Lambert, Professor, Centre of Vaccinology, Centre Médical Universitaire, 1 rue Michel-Servet, CH-1211 Geneva 4, Switzerland
Tel.: +41 22 702 5777; Fax: +41 22 702 5801
Email: paul.lambert@medecine.unige.ch

Dr Deborah Lans, Office of Health and Nutrition, USAID, Ronald Reagan Building, Washington, DC 20523, USA
Tel.: +1 202 712 4625; Fax: +1 202 216 3702
Email: dlans@usaid.gov

Dr Heidi Larson, Senior Communications Adviser, UNICEF, 3 UN Plaza, New York, NY 10017, USA
Tel.: +1 646 207 5179; Fax: +1 212 326 7768
Email: hlarson@unicef.org

Dr Dagna Laufer, Associate Medical Director, Vaccines, Wyeth Ayerst International, 120 N. Radnor-Chester Road, St David’s, CA 19087 USA
Tel.: +1 610 902 4928; Fax: +1 610 964 5670
Email: lauferd@labs.wyeth.com

Dr Hermilo Lopez Coello, Director-General, Laboratorios de Biológicos y Reactivos de México (Birmex), Amores 1240, Col. Del Valle, C.P. 03100, Mexico
Tel.: +52 5 4 22 28 47; Fax: +52 5 4 22 28 81
Email: hcoello@mail.ssa.gob.mx

Dr Myron M. Levine, University of Maryland School of Medicine, 685 W. Baltimore Street, HSF 480, Baltimore, MD 21201, USA
Tel.: +1 410 706 7588; Fax: +1 410 706 6205
Email: mlevine@medicine.umaryland.edu
Dr Orin S. Levine, Epidemiologist, Centers for Disease Control and Prevention, 1600 Clifton Road N.E., Atlanta, GA 30333, USA
Tel.: +1 301 435 7708; Fax: +1 301 496 8030
Email: olevine@niaid.nih.gov

Dr Margaret Liu, Senior Advisor in Vaccinology, Bill and Melinda Gates Foundation, P.O. Box 23350, Seattle, WA 98102, USA
Tel.: +1 206 709 3288; Fax: +1 206 709 3170
Email: margaretiliu@gatesfoundation.org

Dr Christian Loucq, Business Director, Vaccines, Rhein Biotech, Gaetano Martinolaan 95, NL-6229 GS Maastricht, Netherlands
Tel.: +31 43 356 7821; Fax: +31 43 356 7830
Email: c.loucq@rheinbiotech.com

Dr Yvette Madrid, Consultant to the International AIDS Vaccine Initiative, 30 rue de la Gabelle, CH-1227 Carouge, Switzerland
Tel.: +41 22 301 80 30; Fax: +41 22 301 80 33
Email: ymadrid@iavi.org

Dr William Makgoba, President, Medical Research Council of South Africa, P.O. Box 19070, Tygerberg 7505, South Africa
Tel.: +27 21 938 0211/0911; Fax: +27 21 938 0201
Email: malegapuru.makgoba@mvc.ac.za

Mr Jacques-Francois Martin, President, Global Fund for Children’s Vaccines, 36 Quai Fulchiron, F-69005 Lyon, France
Tel.: +33 4 7256 7310; Fax: +33 4 7 842 3424
Email: jfmartin@vaccinefund.org

Ms Harriet Mayanja-Kizza, Senior Lecturer, Makerere Medical School, P.O. Box 7072, Kampala, Uganda
Tel.: +256 77 593482/ 41 534262; Fax: +256 41 533531
Email: hmk@afsat.com

Dr J. M. Mehta, Vice Chairman, Serum Institute of India Ltd., 212/2 Hadapsar, Pune 411 028, Maharashtra, India
Tel.: +91 20 613 4457; Fax: +91 20 613 8992
Email: siexpert@glaspn01.vsnl.net.in

Dr Mark Miller, Director of Research, Fogarty International Center, National Institutes of Health, 31 Center Drive, Room B2C02, Bethesda, MD 20892-2220, USA
Tel.: +1 301 496 1415; Fax: +1 301 402 2173
Email: millermark@nih.gov

Dr Neal Nathanson, Vice-Provost for Research, University of Pennsylvania, Philadelphia, PA 19104-6381, USA
Tel.: +1 215 898 7236; Fax: +1 215 573 2108
Email: nathanmsn@mail.med.upenn.edu

Sir Gustav J.V. Nossal, Professor Emeritus, University of Melbourne, Department of Pathology, Parkville, VIC 3052, Australia
Tel.: +61 3 9344 6946; Fax: +61 3 9347 5242
Email: gnossal@webtime.com.au
Dr Ariel Pablos-Mendez, The Rockefeller Foundation, 420 Fifth Avenue, New York, NY 10018, USA
Tel.: +1 212 852 8348; Fax: +1 212 852 8279
Email: apablos-mendez@rockfound.org

Dr Punnee Pitisuttithum, Chief of Clinical Infectious Diseases Research Unit, Mahidol University, Faculty of Tropical Medicine, 420/6 Rajvithi Road, Rajthavee, Thailand
Tel.: +66 2 2455919; Fax: +66 2 6435598
Email: tmppt@mahidol.ac.th

Dr Thamrin Poeloengan, President-Director, P.T. Bio Farma, Jl. Pasteur No. 28, P.O. Box 1136, Bandung 40161, Indonesia
Tel.: +62 22 233 755; Fax: +62 22 204 1306
Email: thamrin.poeloengan@biofarma.co.id

Dr Regina Rabinovich, Director, Malaria Vaccine Initiative, 6290 Montrose Road, Rockville, MD 20852, USA
Tel.: +1 301 770 5377; Fax: +1 301 770 5322
Email: rrabinovich@malaria vaccine.org

Dr Rino Rappuoli, Chiron SpA, Via Fiorentina 1, I-53100 Siena, Italy
Tel.: +39 0577 243 414; Fax: +39 0577 243 564
Email: rino-rappuoli@biocine.it

Dr Isaias Raw, Director, Instituto Butantan, Av. Vital Brazil 1500, São Paulo 05503 900, Brazil
Tel.: +55 11 813 56 94; Fax: +55 11 815 1505
Email: iraw@quim.ig.usp.br and instbut@aol.com.br

Dr K.I. Varaprasad Reddy, Managing Director, Shantha Biotechnics PVT. Ltd., Serene Chambers, 3rd Floor, Road No. 7, Banjara Hills, Hyderabad 500 034, India
Tel.: +91 40 360 0092; Fax: +91 40 354 1713
Email: varaprasad@shanthabiotech.com

Dr Geoffrey C. Schild, Director, National Institute for Biological Standards and Control, Blanche Lane, South Mimms, GB-Potters Bar, EN6 3QG, United Kingdom
Tel.: +44 1707 646 846; Fax: +44 1707 646854
Email: gschild@nibsc.ac.uk

Dr Alan Shaw, Executive Director, Virus and Cell Biology, Merck Research Laboratories, 770 Summertown Pike, Bldg 14, Room 100, West Point, PA 19486, USA
Tel.: +1 215 652 7400; Fax: +1 215 652 2142
Email: alan-shaw@merck.com

Dr Gustavo Sierra Gonzalez, Vice-President, Investigaciones, and President, Expert Committee for the Cuban Vaccine Programme, Finlay Institute, Centro de Investigación, Producción Vacunas y Sueros, Avenida 27 No. 19805 La Lisa, Ciudad Habana, Cuba
Tel.: +53 7 21 75 97; Fax: +53 7 28 60 75
Email: gsierra@finlay.edu.cu
Dr Eric Simoes, Associate Professor, The Children’s Hospital, Division of Pediatric Infectious Disease, 1056 E. 19th Avenue, B070, Denver, CO 80218, USA
Tel.: +1 303 861 6977; Fax: +1 303 764 8117
Email: eric.simoes@uchsc.edu

Dr Ann-Mari Svennerholm, Göteborg University, Department of Medical Microbiology and Immunology, Guldhedsgatan 10, S-413 46 Göteborg, Sweden
Tel.: +46 31 604724; Fax: +46 31 826976
Email: ann-mari.svennerholm@microbio.gu.se

Professor Dang Duc Trach, Director, National Programme of Immunization, National Institute of Hygiene and Epidemiology, 1 Yersin Street, Hanoi 10 000, Viet Nam
Tel.: +84 4 972 2989; Fax: +84 4 8212 660
Email: trach@fpt.vn

Dr Theodore F. Tsai, Wyeth Ayerst Pharmaceuticals, Global Medical Affairs, 150 N Radnor-Chester Road, St Davids, PA 19087, USA
Tel.: +1 610 902 7138; Fax: +1 610 964 5670
Email: tsait@labs.wyeth.com

Dr Gerald Voss, Senior Scientist for Emerging Diseases, GlaxoSmithKline Biologicals (GSKB), Rue de l’Institut 89, B-1330 Reixensart, Belgium
Tel.: +32 22 656 8243; Fax: +32 2 656 8436
Email: gerald.voss-eyck@gsk.com

Dr Roy Widdus, Manager, Initiative on Public-Private Partnerships for Health, Global Forum for Health Research, International Centre Cointrin, Block G, Third Floor, Case Postale 1826, CH-1215 Geneva 15, Switzerland
Tel.: +41 22 799 4086; Fax: +41 22 799 4089
Email: roy.widdus@ippph.org

Dr Michel de Wilde, Executive Vice-President, Research and Development, Aventis Pasteur, Discovery Drive, Swiftwater, PA 18370, USA
Tel.: +1 570 839 4204; Fax: +1 570 839 5690
Email: michel.dewilde@aventis.com

Dr Peter Wilson, Hillcrest, Guilford Road, GB-Ottershaw KT16 0QL, United Kingdom
Tel.: +44 1932 872 358; Fax: +44 1932 874501
Email: wilsonprb@compuserve.com
WHO Secretariat

Dr M. Teresa Aguado, Coordinator, Vaccine Development (VAD), Vaccines and Biologicals (V&B), Acting IVR Leader
Tel.: +41 22 791 2644; Fax: +41 22 791 4860
Email: aguadom@who.int

Dr Maureen Birmingham, Coordinator, Vaccine Assessment and Monitoring (VAM), V&B
Tel.: +41 22 791 4359; Fax: +41 22 791 4210
Email: birminghamm@who.int

Dr Michael Brennan, VAD/V&B
Tel.: +41 22 791 2169; Fax: +41 22 791 4860
Email: brennannm@who.int

Dr Philippe Calain, Medical Officer, Global Task Force on Cholera Control, Communicable Disease Surveillance and Response, Communicable Diseases (CDS)
Tel.: +41 22 791 2372; Fax: +41 22 791 4667
Email: calainp@who.int

Dr Claire-Lise Chaignat, Coordinator, Global Task Force on Cholera Control, Epidemic Disease Control, CDS
Tel.: +41 22 791 3914; Fax: +41 22 791 4667
Email: chaignatc@who.int

Dr Thomas Cherian, Medical Officer, VAD/V&B
Tel.: +41 22 791 4460; Fax: +41 22 791 4860
Email: cheriant@who.int

Dr John Clements, Medical Officer, Expanded Programme on Immunization (EPI), V&B
Tel.: +41 22 791 4402; Fax: +41 22 791 4193
Email: clementscj@who.int

Ms Maria Dweggah, Secretary, VAD/V&B
Tel.: +41 22 791 2350; Fax: +41 22 791 4860
Email: dweggahm@who.int

Dr Howard Engers, Manager, Steering Committee on Vaccine Discovery Research, Special Programme for Research and Training in Tropical Diseases (TDR), CDS
Tel.: +41 22 791 3736; Fax: +41 22 791 4854
Email: engersh@who.int

Dr José Esparza, Coordinator, WHO-UNAIDS HIV Vaccine Initiative
Tel.: + 41 22 791 4392; Fax: +41 22 791 4865
Email: esparzaj@who.int

Dr Uli Fruth, Medical Officer, VAD/V&B
Tel.: +41 22 791 2678; Fax: +41 22 791 4860
Email: fruthu@who.int

* Certain WHO staff participated only in selected sessions.
Dr Peter Graaf, Regional Adviser for Essential Drugs and Biologicals, WHO Regional Office for the Eastern Mediterranean, WHO Post Office, Abdul Razzak Al Sanhouri Street, Nasr City, P.O. Box 7608, Cairo 11371, Egypt
Tel.: +202 276 3301; Fax: +202 670 24 92
Email: graaffp@emro.who.int

Dr Elwyn Griffiths, Coordinator, Quality Assurance and Safety of Biologicals (QSB), V&B
Tel.: +41 22 791 3890; Fax: +41 22 791 4971
Email: griffithse@who.int

Dr David L. Heymann, Executive Director, CDS
Tel.: +41 22 791 2212; Fax: +41 22 791 4752
Email: heymannnd@who.int

Dr Bernard Ivanoff, Medical Officer, VAD/V&B
Tel.: +41 22 791 2698; Fax: +41 22 791 4860
Email: ivanoffb@who.int

Dr Luis Jódar, Scientist, VAD/V&B
Tel.: +41 22 7913744; Fax: +41 22 791 4860
Email: lodarj@who.int

Dr Juntra Karbwang, Clinical Coordinator, Product Research and Development, TDR/CDS
Tel.: +41 22 791 3868; Fax: +41 22 791 4854
Email: karbwangj@who.int

Dr Ulla Kou, Associate Professional Officer, VAM/V&B
Tel.: +41 22 791 4289; Fax: +41 22 791 4210
Email: kouu@who.int

Dr Bjorn Melgaard, Director, V&B
Tel.: +41 22 791 4408; Fax: +41 22 791 4227
Email: melgaardb@who.int

Dr Julie Milstien, Coordinator, Access to Technologies (ATT), V&B
Tel.: +41 22 791 3564; Fax: +41 22 791 4384
Email: milstienj@who.int

Dr Jean-Marie Okwo-Bele, Regional Adviser, EPI, Parirenyatwa Hospital, Mazoe Street, P.O. Box, BE 773, Belvedere Harare, Zimbabwe
Tel.: +1 321 733 9384; Fax: +263 49 0146
Email: okwob@whoafr.org

Ms Karen O'Leary, Informatics, V&B
Tel.: +41 22 791 4414; Fax: +41 22 791 4860
Email: olearyk@who.int

Dr Otavio Oliva, Regional Advisor RDV/SVI, WHO Regional Office for the Americas, Pan American Sanitary Bureau, 525 23rd Street N.W., Washington, DC 20037, USA
Tel.: +1 202 974 3707; Fax: +1 202 974 3635
Email: oliviaota@paho.org
Dr Sonia Pagliusi, Scientist, VAD/V&B
Tel.: +41 22 791 3718; Fax: +41 22 791 4860
Email: pagliusis@who.int

Dr Yuri Pervikov, Medical Officer, VAD/V&B
Tel.: +41 22 791 2601; Fax: +41 22 791 4860
Email: pervikovy@who.int

Dr Ciro de Quadros, Director, Division of Vaccines and Immunization, WHO Regional Office for the Americas/Pan American Sanitary Bureau
525 23rd Street N.W., Washington, DC 20037, USA
Tel.: +1 202 974 3247; Fax: +1 202 974 3635
Email: quadrosc@paho.org

Dr Klaus Stohr, Epidemic Disease Control, CDS
Tel.: +41 22 791 2529; Fax: +41 22 791 4878
Email: stohrk@who.int

Dr Yasuhiro Suzuki, Executive Director, Health Technology and Pharmaceuticals (HTP)
Tel.: +41 22 791 2511; Fax: +41 22 791 4889
Email: suzukiy@who.int

Dr Jay Wenger, EPI/V&B
Tel.: +41 22 791 4511; Fax: +41 22 791 4193
Email: wengerj@who.int

Ms Claire Whitfield, Secretary, VAD/V&B
Tel.: +41 22 791 3718; Fax: +41 22 791 4860
Email: whitfieldc@who.int

Dr David Wood, Principal Scientist, QSB/V&B
Tel.: +41 22 791 4050; Fax: +41 22 791 4971
Email: woodd@who.ch

Mr Michel Zaffran, Programme Manager, V&B
Tel.: +41 22 791 4373; Fax: +41 22 791 4227
Email: zaffranm@who.int
The Department of Vaccines and Biologicals was established by the World Health Organization in 1998 to operate within the Cluster of Health Technologies and Pharmaceuticals. The Department’s major goal is the achievement of a world in which all people at risk are protected against vaccine-preventable diseases.

Five groups implement its strategy, which starts with the establishment and maintenance of norms and standards, focusing on major vaccine and technology issues, and ends with implementation and guidance for immunization services. The work of the groups is outlined below.

The Quality Assurance and Safety of Biologicals team ensures the quality and safety of vaccines and other biological medicines through the development and establishment of global norms and standards.

The Initiative for Vaccine Research and its three teams involved in viral, bacterial and parasitic diseases coordinate and facilitate research and development of new vaccines and immunization-related technologies.

The Vaccine Assessment and Monitoring team assesses strategies and activities for reducing morbidity and mortality caused by vaccine-preventable diseases.

The Access to Technologies team endeavours to reduce financial and technical barriers to the introduction of new and established vaccines and immunization-related technologies.

The Expanded Programme on Immunization develops policies and strategies for maximizing the use of vaccines of public health importance and their delivery. It supports the WHO regions and countries in acquiring the skills, competence and infrastructure needed for implementing these policies and strategies and for achieving disease control and/or elimination and eradication objectives.